Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · Alps

ALPS Medical Breakthroughs ETF (SBIO)

Ticker SBIO · · Holdings as of May 31, 2026

Expense ratio
0.5%$50/yr per $10k
5-yr return
+0.7%annualized
1-yr return
+54.2%as of Dec 2025
Net assets
$161.8Mall share classes
Holdings
89

Bottom line

Is SBIO a good fund? The bottom line

SBIO is a managed health care sector ETF from Alps.

It charges 0.5% — about $50 a year on every $10,000 invested, cheaper than 81% of health care sector funds we track.

It returned +54.2% over one year, +0.7% a year over five years, +5.7% a year over ten (as of Dec 31, 2025, per its prospectus).

With $162 million in net assets and 89 holdings, its largest position is Alkermes Plc (4.5%) and the top 10 make up 34.8% of the portfolio.

What stands out

  • Low cost: cheaper than 81% of health care sector peers

What to watch

  • 5-year return in the bottom quarter of its category

Updated Nov 19, 2026

What SBIO invests in

The Fund seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (ticker symbol PMBI) (the Underlying Index).

The Fund employs a passive management or indexing investment approach designed to track the performance of the Underlying Index. The Underlying Index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration (FDA) clinical trials. In a Phase II trial, the drug is administered to a group of 100-300 people to see if it is effective and to evaluate its safety. In a Phase III trial, the drug is given to a larger group, between 500-3,000 people, to confirm its effectiveness, monitor side effects, compare it to commonly used treatments and collect information that will allow the drug or treatment to be used safely. Stocks selected for inclusion in the Underlying Index must be listed on a U.S. stock exchange. Underlying Index constituents must have a market capitalization of no less…

From the fund's prospectus (filed Mar 30, 2026).

SBIO performance

Fund calendar-year total returns, 2016–2025 2016: −27.7%; 2017: +44.9%; 2018: −11.2%; 2019: +49.9%; 2020: +21.2%; 2021: −17.5%; 2022: −27.9%; 2023: +8.2%; 2024: +4.2%; 2025: +54.2% −28% 2016 +45% 2017 −11% 2018 +50% 2019 +21% 2020 −18% 2021 −28% 2022 +8% 2023 +4% 2024 +54% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
SBIO+54.2%+0.7%+5.7%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full SBIO performance history →

What SBIO costs

On a $10,000 investment, SBIO's 0.5% expense ratio costs about $50 a year. The prospectus estimates $628 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full SBIO fee table →

SBIO top 10 holdings

#Holding% of fund
1Alkermes Plc4.48%
2Kymera Therapeutics Inc4.23%
3Celcuity Inc3.92%
4Mirum Pharmaceuticals Inc3.90%
5Spyre Therapeutics Inc3.68%
6Cg Oncology Inc3.35%
7Apogee Therapeutics Inc2.93%
8Xenon Pharmaceuticals Inc2.90%
9Travere Therapeutics Inc2.77%
10Dianthus Therapeutics Inc2.64%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 34.8% of the fund. See all top 25 holdings and asset mix →

Alternatives to SBIO

More funds like SBIO →

SBIO FAQ

What is the expense ratio of SBIO?
SBIO's expense ratio is 0.5%, which works out to about $50 a year for every $10,000 invested. The prospectus estimates total costs of $628 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is SBIO a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 81% of health care sector peers; 5-year return in the bottom quarter of its category. This is general information, not personalized advice.
What does SBIO hold?
SBIO's largest holdings are Alkermes Plc (4.5%), Kymera Therapeutics Inc (4.2%), Celcuity Inc (3.9%), Mirum Pharmaceuticals Inc (3.9%), Spyre Therapeutics Inc (3.7%). It holds 89 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is SBIO's 5-year return?
SBIO returned +0.7% a year over the five years ending Dec 31, 2025, and +5.7% a year over ten years. Past performance does not guarantee future results.
Who manages SBIO?
SBIO is offered by Alps through ALPS ETF Trust.